Education
About Us
Working with TipRanks
Follow Us
Pfizer Inc (PFE)
NYSE:PFE
Earnings Data
Report Date
May 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.73Last Year’s EPS
0.92Same Quarter Last Year
Based on 20 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong positives — better‑than‑expected adjusted EPS, margin expansion, meaningful cost‑savings realization, promising obesity (PF‑3944) clinical readouts with differentiated monthly dosing, robust activity on pivotal studies and approvals, and strategic acquisitions that are already contributing revenue growth. Offsetting these strengths are near‑term challenges: modest overall revenue decline (driven largely by a pronounced COVID revenue drop), a sizable $4.4 billion impairment reflecting portfolio reprioritization, upcoming LOE pressure (including ~ $1.5 billion revenue compression projected in 2026), and some GAAP volatility in the quarter. On balance, the company reinforced a clear strategic plan, reaffirmed 2026 guidance, and emphasized productivity/AI initiatives and reinvestment into high‑impact R&D, suggesting the positives materially outweigh the near‑term negatives.Company Guidance
Exceeded Financial Expectations and Shareholder Returns
Full year 2025 adjusted diluted EPS of $3.22 versus $3.11 in 2024 (ahead of expectations); returned $9.8 billion to shareholders via dividends; invested $10.4 billion in internal R&D and ~$8.8 billion in business development.
Revenue Performance Excluding COVID: Positive Operational Growth
Full year 2025 operational revenue grew 6% when excluding COVID-19 products; non-COVID product revenue for Q4 grew 9% operationally versus prior year.
Strong Contribution from Recently Launched and Acquired Products
Recently launched and acquired products delivered $10.2 billion in revenues for 2025 and grew approximately 14% operationally versus prior year.
Margin Expansion and Cost Savings Progress
Full year adjusted gross margin expanded to 76%; achieved approximately $600 million in savings from phase one of the manufacturing optimization program through 2025 and expects total manufacturing savings of $1.5 billion by 2027.
Promising Obesity (Metsera / PF-3944) Clinical Data
VESPER (VESPA) three placebo‑adjusted weight loss of 10.0%–12.3% at week 28 for the low and medium monthly maintenance doses; model predicts ~16% placebo‑adjusted weight loss at week 28 for the high monthly dose (9.6 mg); safety profile favorable with predominantly mild/moderate GI AEs and low discontinuations.
Robust R&D and Pipeline Activity
2025 saw 40 approvals/critical readouts and initiation of 11 pivotal studies; company anticipates ~20 pivotal studies in 2026 (10 in the Metsera portfolio) and key readouts across oncology, obesity, and vaccines.
Commercial and Therapeutic Leadership Signals
Nurtec captured 83% of new CGRP writer volume in Q4 and led new patient starts in the oral CGRP class; PADCEV (PATCEV) achieved an FDA approval in a new muscle‑invasive bladder cancer indication, with potential to expand the US addressable population by ~22,500 patients if additional approvals succeed.
Scaling AI to Improve Productivity
Company is expanding AI compute to >1,200 GPUs, embedding AI across discovery, development, manufacturing, and commercial functions to accelerate speed, reduce costs, and improve productivity; AI cited as contributor to manufacturing and commercial efficiency gains.
Reaffirmed 2026 Guidance
2026 full year revenue guidance reaffirmed at $59.5 billion–$62.5 billion and adjusted diluted EPS guidance of $2.80–$3.00; non‑COVID & non‑LOE revenues at midpoint expected to grow ~4% operationally year‑over‑year.
PFE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PFE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 03, 2026 | $26.66 | $25.77 | -3.34% |
Nov 04, 2025 | $23.83 | $23.49 | -1.46% |
Aug 06, 2025 | $23.92 | $23.13 | -3.32% |
Apr 29, 2025 | $21.49 | $22.18 | +3.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pfizer Inc (PFE) report earnings?
Pfizer Inc (PFE) is schdueled to report earning on May 05, 2026, Before Open (Confirmed).
What is Pfizer Inc (PFE) earnings time?
Pfizer Inc (PFE) earnings time is at May 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PFE EPS forecast?
PFE EPS forecast for the fiscal quarter 2026 (Q1) is 0.73.
